TNGX Q1 2022 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-9.8% YoY

Gross Profit

$5M88.4% margin

Operating Income

-$25M-440.8% margin

Net Income

-$25M-437.8% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$472M

Total Liabilities

$151M

Stockholders' Equity

$320M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$6M	-9.8%
Gross Profit	$5M	$6M	-14.3%
Operating Income	-$25M	-$12M	-110.1%
Net Income	-$25M	-$12M	-108.2%